Ron in the News

Study Points to New Strategy for Boosting Immunotherapy Effectiveness in Advanced Colorectal Cancer

Findings demonstrate how two cancer-related genes interact to spur metastasis and potentially enhance immune checkpoint blockade treatment MD Anderson News Release March 21, 2019 Researchers at The University of Texas MD Anderson Cancer Center revealed the common oncogene KRAS as a possible explanation for why many patients with metastatic colorectal cancer (CRC) do not respond …

Study Points to New Strategy for Boosting Immunotherapy Effectiveness in Advanced Colorectal Cancer Read More »

Do the Caps of Your Chromosomes Hold the Secret to More Years?

In July, Outside magazine ran a profile of a woman named Elizabeth Parrish. “Liz Parrish Wants to Live Forever,” the headline shouted. A few years earlier, in 2015, Parrish had become the first human guinea pig in an experiment intended to reverse aging through gene therapy. She, and the scientists who designed the therapy, were …

Do the Caps of Your Chromosomes Hold the Secret to More Years? Read More »

Former M.D. Anderson president’s new Houston company names first CEO

Houston-based biopharmaceutical company Tvardi Therapeutics Inc., which was co-founded by former University of Texas M.D. Anderson Cancer Center president Dr. Ronald DePinho, named Imran Alibhai as its CEO, effective immediately. Alibhai most recently served as a senior vice president and managing director of Houston-based DNAtrix Inc., a clinical-stage biopharmaceutical company developing oncolytic viruses for cancer, …

Former M.D. Anderson president’s new Houston company names first CEO Read More »

Nobel Prize Ceremony

It was an honor to be in Stockholm to see my good friend, Dr. Jim Allison, receive the Nobel Prize for his lifesaving work in immunotherapy. A very exciting moment for all cancer researchers and patients. Thank you Jim for your devotion to saving lives. Making Cancer History! Check out the below videos for an …

Nobel Prize Ceremony Read More »

Former M.D. Anderson president: ‘We need the private sector’

Ron DePinho, a current professor and past president of the University of Texas M.D. Anderson Cancer Center, founded a private cancer drug company that recently closed a $9 million funding round. Tvardi Therapeutics Inc. develops a cancer drug that acts as an inhibitor to STAT3 — a signaling molecule in our cells that, when left …

Former M.D. Anderson president: ‘We need the private sector’ Read More »

MD Anderson pioneer and newly minted Nobel Laureate Dr. James Allison is truly making cancer history

As longtime supporters of the University of Texas MD Anderson Cancer Center, it gives us a sense of pride and accomplishment to see the great work of our very own Dr. Jim Allison recognized with the 2018 Nobel Prize in Medicine. This is the first such prize awarded to an MD Anderson scientist, and we …

MD Anderson pioneer and newly minted Nobel Laureate Dr. James Allison is truly making cancer history Read More »

Thank you, Jim Allison

Thanks to Jim, immune checkpoint therapy has transformed not only our institution but the entire cancer field, providing a revolutionary new treatment strategy and real hope for countless cancer patients. In addition, Jim’s story stands as one of the best examples of the importance of sustained investment in basic biomedical research. Guest Editorial: Cancer-Letter-10.5.18

Get Insights From Ron

Sign up for the latest news and updates from Ron DePinho, MD